Marc Ladanyi
Department of Pathology and Human Oncology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center
New York
New York 10065
USA
Name/email consistency: high
- CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Ladanyi, M. Cancer. Discov (2011)
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Ladanyi, M., Pao, W. Mod. Pathol. (2008)
- Targeted therapy of cancer: new roles for pathologists. Ladanyi, M. Mod. Pathol. (2008)
- Implications of P16/CDKN2A deletion in pleural mesotheliomas. Ladanyi, M. Lung. Cancer (2005)
- Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Ladanyi, M., Antonescu, C.R., Leung, D.H., Woodruff, J.M., Kawai, A., Healey, J.H., Brennan, M.F., Bridge, J.A., Neff, J.R., Barr, F.G., Goldsmith, J.D., Brooks, J.S., Goldblum, J.R., Ali, S.Z., Shipley, J., Cooper, C.S., Fisher, C., Skytting, B., Larsson, O. Cancer Res. (2002)
- EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Ladanyi, M. Cancer Biol. Ther. (2002)
- Expression profiling of human tumors: the end of surgical pathology?. Ladanyi, M., Chan, W.C., Triche, T.J., Gerald, W.L. J. Mol. Diagn (2001)
- Fusions of the SYT and SSX genes in synovial sarcoma. Ladanyi, M. Oncogene (2001)
- Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. Ladanyi, M. Am. J. Pathol. (2000)
